



You are either a believer...
...or you're not


There are many nihilists across the land













Grea	Greater Saphenous Vein								
	Primary Graft Patency @ 5 years	Secondary Graft Patency @ 5 years	Limb Salvage @ 5 years						
Taylor et al. (JVS 1990) n = 300 reversed GSV	80%	84%	90%						
Shah et al. (Ann Surg 1995) n = 2048 in situ GSV	72%	81%	95%						














					(BEST-CLI			
Procedural Charactertistiscs : Bypass (ITT)									
	Cohort 1			Cohort 2					
Surgical Bypass Details, n(%)	Overall (N=1395)	Open (N=687)	Endo (N=708)	Overall (N=385)	Open (N=190)	Endo (N=196			
Bypass using SSGSV	639 (45.8)	581 (84.6)	58 (8.2)	45 (11.7)	37 (19.5)	8 (4.1)			
Bypass using alternative Vein	31 (2.2)	31 (4.5)	0 (0.0)	48 (12.5)	40 (21.1)	8 (4.1)			
Bypass conduit Prostheti	ic Coho	rt 1 & 2	2: 169 /	877 (1	19%)	5 (2.6) 14 (7.2)			
Above the knee Femoropopliteal Bypass	116 (8.3)	105 (15.3)	11 (1.6)	46 (11.9)	44 (23.2)	2 (1.0)			
Below the knee Femoropopliteal Bypass	191 (13.7)	170 (24.7)	21 (3.0)	59 (15.3)	47 (24.7)	12 (6.2)			











BWH Unpublished Exper	ience: 200	7-2017, n=62
	Distaflo (35	Propaten(27)
• 3-year Primary Patency:	48%	76% (0.04)
• 3-year Limb Salvage:	73%	75% (0.43)

